Civilization Ventures (inquiries to [email protected]) invests in visionary founders that are leading the future of health tech and biology-driven innovation. We aim to be the first check and lead investor in highly disruptive companies in synthetic biology and exponential health tech (genomics, diagnostics, digital health, AI, personalized and regenerative medicine). Our team comprises serial entrepreneurs and industry thought leaders who work tirelessly to help each of our portfolio companies succeed. We celebrated our first "unicorn" exit in 2018 with the public listing of gene therapy leader Rocket Pharma (NASDAQ: RCKT) and our second exit with the acquisition of Singular Bio (non-invasive prenatal testing) by Invitae.
Civilization Ventures
Venture CapitalCV invests in visionary founders in digital health/AI, synthetic biology + diagnostics. ([email protected])
Founded 2017
San Francisco, United States
5 employees
Health Care
San Francisco, United States
5 employees
Health Care
46
Total Investments
33
Portfolio Companies
-
Exits
1
Industries
General Information
Industries
Health Care
Funding Stage
Seed +2
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Civilization Ventures
Recent Investments (46)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series A | •••••• | Aug 2025 | |
| Series C | •••••• | Jun 2025 | |
| Series B | •••••• | Aug 2024 | |
| Series B | •••••• | Jul 2024 | |
| Series D | •••••• | Jun 2024 | |
•••• ••••
|
Pre Seed Round | •••••• | May 2024 |
|
•••• ••••
|
Seed Round | •••••• | May 2024 |
|
•••• ••••
|
Seed Round | •••••• | Feb 2024 |
|
•••• ••••
|
Seed | •••••• | Nov 2023 |
|
•••• ••••
|
Convertible Note | •••••• | Oct 2023 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
